# Distinct Laboratory and Clinical Features of Metabolic and Alcohol-Related Liver Disease (MetALD): A Systematic Review and Meta-Analysis

**Authors:** Maria Tampaki, Vasileios Lekakis, Christos Chologkitas, Stergios Α. Polyzos, Evangelos Cholongitas

PMC · DOI: 10.1007/s13679-026-00696-6 · 2026-03-06

## TL;DR

This study compares the liver disease MetALD with MASLD and ALD, finding distinct lab and metabolic features that suggest MetALD is a unique condition.

## Contribution

The study identifies specific laboratory and metabolic differences between MetALD and other liver diseases, supporting its classification as a distinct subtype.

## Key findings

- MetALD shows higher AST, ALT, GGT, triglycerides, and HDL-C compared to MASLD.
- Compared to ALD, MetALD has lower liver enzymes but similar metabolic parameters.
- MetALD has lower BMI and HbA1c than MASLD but higher blood pressure.

## Abstract

We aimed to perform a systematic review and meta-analysis of observational studies, primarily to compare laboratory findings, including liver function tests, and metabolic parameters, between patients with Metabolic and alcohol-related/associated liver disease (MetALD) and those with metabolic dysfunction-associated steatotic liver disease (MASLD) or alcohol-related liver disease (ALD).

MetALD is a newly recognized subtype of steatotic liver disease (SLD) characterized by the synergistic impact of metabolic dysfunction and alcohol consumption. Data on its clinical and laboratory profile remain limited.

Thirty-three studies including 7,504,674 individuals were analyzed. Compared to MASLD, MetALD was associated with higher aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), higher triglycerides (TG) and high density lipoprotein-cholesterol (HDL-C), lower low density lipoprotein-cholesterol (LDL-C), and higher systolic and diastolic blood pressure, but lower body mass index (BMI) and hemoglobin A1c (HbA1c). Compared to ALD, MetALD showed lower liver enzymes, while most metabolic parameters were similar.

MetALD has distinct laboratory and metabolic features compared to MASLD, while differences with ALD are less pronounced. These findings favor MetALD as a distinct entity warranting further, more focused research.

The online version contains supplementary material available at 10.1007/s13679-026-00696-6.

## Linked entities

- **Diseases:** metabolic dysfunction-associated steatotic liver disease (MONDO:0013209)

## Full-text entities

- **Genes:** SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, NOS1 (nitric oxide synthase 1) [NCBI Gene 4842] {aka IHPS1, N-NOS, NC-NOS, NOS, bNOS, nNOS}, GGTLC4P (gamma-glutamyltransferase light chain 4 pseudogene) [NCBI Gene 729838] {aka GGT}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}
- **Diseases:** Insulin Resistance (MESH:D007333), CVD (MESH:D002318), atherosclerosis (MESH:D050197), hypertension (MESH:D006973), liver axis dysfunction (MESH:D017093), muscle loss (MESH:D009135), hepatocellular injury (MESH:D056486), adiposity (MESH:D018205), Metabolic and Alcohol-Related Liver Disease (MESH:D008108), T2DM (MESH:D003924), hepatic fibrosis (MESH:D008103), endothelial dysfunction (MESH:D014652), Diabetes (MESH:D003920), NAFLD (MESH:D065626), mitochondrial dysfunction (MESH:D028361), alcohol (MESH:D000437), dyslipidemia (MESH:D050171), metabolic syndrome (MESH:D024821), Fibrosis (MESH:D005355), adipose tissue inflammation (MESH:D007249), MASLD (MESH:D008107), sarcopenia (MESH:D055948), Visceral adiposity (MESH:D007418), loss of muscle mass (MESH:C536030), metabolic (MESH:D008659), Obesity (MESH:D009765), Fatty Liver (MESH:D005234)
- **Chemicals:** PEth (MESH:C051521), Peth (-), glucose (MESH:D005947), alcohol (MESH:D000438), lipid (MESH:D008055), TG (MESH:D014280), TGs (MESH:C026285), cholesterol (MESH:D002784)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** A1C

## Figures

14 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12966208/full.md

---
Source: https://tomesphere.com/paper/PMC12966208